Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 161 - 170 of 333

<< Previous | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | Next >>

Last updated: 20th February 2008

Patent No.: US 6627621
Neutrophil function inhibitors.
Applicant: Nagaoka I, Sakamoto K (2003)
Glucosamine salts are effective for the inhibition of neutrophil functions, and hence, are useful for the prevention and/or treatment of diseases, caused as a result of an excessive extracellular release of active oxygen and antibiotic proteins by neutrophils, such as respiratory disease syndrome and adult respiratory disease syndrome. Use of glucosamine salts can, therefore, provide neutrophil function inhibitors, preventives and/or remedies for diseases caused as a result of an excessive extracellular release of active oxygen and antibiotic proteins by neutrophils, and also methods for the prevention and/or treatment of such diseases.

Patent No.: US 6624140
Synthetic peptides with antimicrobial and endotoxin neutralizing properties for management of the sepsis syndrome.
Applicant: Abraham PR, Appelmelk BJ, Van Deventer SJH (2003)
A peptide with an amino acid composition such that the peptide is amphipathic, cationic and forms a stable .alpha.-helix and has the following structure comprising at least 12 amino acids R.sub.1 -R.sub.2 -A.sub.1 -B.sub.1 -(A.sub.2 -B.sub.2 -C.sub.1 -A.sub.3).sub.m -(C.sub.2).sub.n -R.sub.3, wherein A=an amino acid selected from the basic amino acids Lys,Arg or His B=an amino acid selected from the aromatic amino acids Phe, Trp or Tyr C=an amino acid selected from the group comprising the hydrophobic amino acids Leu, Ile, Val or Ala, and said peptide has either the orientation according to the formula or the retro orientation thereof, wherein at least 0-m of the repetitive sequence motifs (A.sub.2 -B.sub.2 -C.sub.1 -A.sub.3) have the retro orientation and the remaining repetitive motifs (A.sub.2 -B.sub.2 -C.sub.1 -A.sub.3) have the orientation as presented in the formula and wherein, R.sub.1 -R.sub.2 - and R.sub.3 are a number of amino acids, and wherein m=1-10, preferably 2-8, more preferably 2-5 and n=1-3, a pharmaceutical composition comprising such a peptide application thereof in treatment or diagnosis related to i.a. parasite infection topical and systemic tumors and septic shock.

Patent No.: US 6607879
Compositions for the detection of blood cell and immunological response gene expression.
Applicant: Cocks BG, Stuart SG, Seilhamer JJ (2003)
The present invention relates to a composition comprising a plurality of polynucleotide probes. The composition can be used as hybridizable array elements in a microarray. The present invention also relates to a method for selecting polynucleotide probes for the composition.

Patent No.: US 6605698
Antifungal peptides and composition thereof.
Applicant: Van Amerongen A, Fant F, Borremans FA, De Samblanx GW, Sijtsma L, Meloen RH, Puijk WC, Schaaper WMM, Broekaert WF, van Gelder WMJ, Rees SB (2003)
Antifungal peptides which comprise at least six amino acid residues identical to a run of amino acid residues found between position 21 and position 51 of the Rs-AFP2 antifungal protein sequence or of substantially homologous protein sequences. The peptides are useful for combating fungal diseases in agricultural, pharmaceutical or preservative applications.

Patent No.: US 6600090
Transgenic plants expressing puroindolines and methods for producing such plants.
Applicant: Giroux MJ, Sherwood JE, Krishnamurthy K, Morris CF (2003)
This invention relates to plant cells, plant tissues or plants transgenic for a nucleic acid encoding a puroindoline. This invention also relates to methods of producing such transgenic plant cells, plant tissues or plants. The transgenic plants produced by the methods of this invention are useful in reducing the damage caused by plant pests, especially plant pathogens such as fungi and bacteria.

Patent No.: US 6590078
DNA sequences, vectors, and fusion polypeptides for secretion of polypeptides in filamentous fungi.
Applicant: Ward M, Power SD (2003)
The invention includes novel fusion nucleic acids encoding fusion polypeptides which when expressed in a filamentous fungus result in the expression of fusion polypeptides. The fusion nucleic acids comprise four nucleic acids which encode a fusion polypeptide comprising first, second, third and fourth amino acid sequences. The first nucleic acid encodes a signal polypeptide functional as a secretory sequence in a first filamentous fungus. The second nucleic acid encodes a secreted polypeptide or functional portion thereof which is normally secreted from the same filamentous fungus or a second filamentous fungus. The third nucleic acid encodes a cleavable linker while the fourth nucleic acid comprises at least two nucleic acids encoding desired polypeptides.

Patent No.: US 228660
Eukaryotic signal peptide sequences for improving recombinant polypeptide secreted expression and polypeptide display libraries.
Applicant: Gray J, Buechler J, Veeramallu UK (2003)
The present invention generally relates to methods and compns. for expressing proteins or polypeptides in prokaryotic hosts using eukaryotic signal sequences. In particular embodiments, the invention provides improved methods of displaying a Fab fragment from a phage by including eukaryotic signal peptide sequence to promote efficient secretion of proteins in a bacterial host. Specifically, r-Methamphetamine monoclonal antibodies rMET1 or rMET10 are cloned and prepd. from phage display libraries using a plasmid vector designated AL2.2 which contains a rhamnose promoter operably linked to a dicistronic transcriptional unit encoding an antibody heavy chain and an antibody light chain. The light chain is operably linked to a first signal peptide sequence, and the heavy chain is operably linked to a phage outersurface protein and a second signal peptide sequence. Also disclosed are three selected eukaryotic signal peptides and their encoding cDNA sequences from human Ceruloplasmin precursor; human Neutrophil defensin 1, 2, 3; and Chlamydomonas reinhardtii Arylsulfatase precursor. Also provided are methods for polyclonal phage enrichment of polyclonal phage to matrix metalloproteinase 9 precursor (Pro-MMP9) having eukaryotic signal sequences. In addn., methods for cloning, expression, purifn. and biotinylation of human matrix metalloproteinase-9 precursor (Pro-MMP9), or cloning of Macaque IL-8 antigens are provided.

Patent No.: US 175755
Methods for detecting mutations in human beta defensin 2 gene promoter associated with increased susceptibility to periodontal disease and data evaluation.
Applicant: Abiko Y, Kaku T, Arakawa T, Takuma T, Nishimura M, Kusano K (2003)
Methods for detecting mutations in beta defensin 2 gene promoter assocd. with increased susceptibility to periodontal disease and data evaluation. The sequence homol. between DNA derived from a defensin gene promoter existing in a sample obtained from the gingival tissues of a subject and a nucleotide sequence comprising a mutation site in the promoter region, and/or compatibility in PCR amplification, are detd. Thereby a gene mutation is detected and then the site of the gene mutation is detd., so that data for the estn. can be collected.

Patent No.: US 143234
Anti-microbial targeting chimeric pharmaceutical peptides.
Applicant: Shi W, Morrison SL, Trinh K, Wims L, Chen L, Anderson M, Qi F (2003)
The present invention is based on the discovery of a compn. that provides targeted anti-microbial effect. Specifically the compn. contains a targeting moiety which recognizes a target microbial organism and an anti-microbial peptide moiety which has anti-microbial activity. In addn., the present invention provides methods of treating a microbial infection, e.g., on mucosal surfaces by using the compns. provided by the present invention.

Patent No.: US 140368
Protein and cDNA sequences of plant defensins and uses for enhancing plant pathogen defense systems.
Applicant: Famodu OO, Herrmann R, Lu AL, McCutchen BF, Miao G-H, Presnail JK, Rafalski JA, Weng Z (2003)
This invention relates to isolated nucleic acids encoding plant defensins and uses for enhancing resistance to plant pathogens. The invention also relates to the construction of a chimeric gene encoding all or a portion of the plant defensin, in sense or antisense orientation, wherein expression of the chimeric gene results in prodn. of altered levels of plant defensins in a transformed host cell.